(Q83001629)

English

Cost-effectiveness modeling of abatacept versus other biologic agents in DMARDS and anti-TNF inadequate responders for the management of moderate to severe rheumatoid arthritis

scientific article published on 17 December 2008

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19089488%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Cost-effectiveness modeling of abatacept versus other biologic agents in DMARDS and anti-TNF inadequate responders for the management of moderate to severe rheumatoid arthritis (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19089488%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

4

object named as

Boulos Haraoui

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19089488%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

author name string

Anthony Russell

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19089488%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Ariel Beresniak

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19089488%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Louis Bessette

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19089488%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Proton Rahman

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19089488%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Carter Thorne

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19089488%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Ross Maclean

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19089488%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Danielle Dupont

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19089488%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

publication date

17 December 2008

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19089488%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Clinical Rheumatology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19089488%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

28

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19089488%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19089488%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

403-412

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19089488%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Dose intensification with infliximab in patients with rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19089488

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/19089488

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The Disease Activity Score and the EULAR response criteria

1 reference

https://pubmed.ncbi.nlm.nih.gov/19089488

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The costs of rheumatoid arthritis: an international long-term view

1 reference

https://pubmed.ncbi.nlm.nih.gov/19089488

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Economic evaluation of programs or interventions in the management of rheumatoid arthritis: defining a consensus-based reference case.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19089488

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rheumatoid arthritis therapy after tumor necrosis factor and interleukin-1 blockade

1 reference

https://pubmed.ncbi.nlm.nih.gov/19089488

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Guidelines for the management of rheumatoid arthritis: 2002 Update

1 reference

https://pubmed.ncbi.nlm.nih.gov/19089488

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19089488

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Limitations of the methods used for calculating quality-adjusted life-year values

1 reference

https://pubmed.ncbi.nlm.nih.gov/19089488

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Modeling the 5-year cost effectiveness of treatment strategies including tumor necrosis factor-blocking agents and leflunomide for treating rheumatoid arthritis in the Netherlands

1 reference

https://pubmed.ncbi.nlm.nih.gov/19089488

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/19089488

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19089488

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/19089488

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rating of arthritis health states by patients, physicians, and the general public. Implications for cost-utility analyses.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19089488

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19089488

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Review of eight pharmacoeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19089488

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19089488

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Etanercept: a pharmacoeconomic review of its use in rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19089488

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period

1 reference

https://pubmed.ncbi.nlm.nih.gov/19089488

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

1 reference

https://pubmed.ncbi.nlm.nih.gov/19089488

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An overview of economic evaluations for drugs used in rheumatoid arthritis : focus on tumour necrosis factor-alpha antagonists

1 reference

https://pubmed.ncbi.nlm.nih.gov/19089488

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Progress in the treatment of rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19089488

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Assessing utility values in rheumatoid arthritis: A comparison between time trade-off and the EuroQol

1 reference

https://pubmed.ncbi.nlm.nih.gov/19089488

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose escalation of the anti-TNF-alpha agents in patients with rheumatoid arthritis. A systematic review

1 reference

https://pubmed.ncbi.nlm.nih.gov/19089488

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Review of health economics modelling in rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19089488

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Infliximab dose and clinical status: results of 2 studies in 1642 patients with rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19089488

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Minimal disease activity for rheumatoid arthritis: a preliminary definition

1 reference

https://pubmed.ncbi.nlm.nih.gov/19089488

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The use of infliximab in academic rheumatology practice: an audit of early clinical experience

1 reference

https://pubmed.ncbi.nlm.nih.gov/19089488

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Advantages and limitations of utility assessment methods in rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19089488

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Frequency of remissions in early rheumatoid arthritis defined by 3 sets of criteria. a 5-year followup study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19089488

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Modelling methods for pharmacoeconomics and health technology assessment: an overview and guide

1 reference

https://pubmed.ncbi.nlm.nih.gov/19089488

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19089488

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Modelling the cost effectiveness of TNF- antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry

1 reference

https://pubmed.ncbi.nlm.nih.gov/19089488

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

1 reference

https://pubmed.ncbi.nlm.nih.gov/19089488

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

QALYs: are they helpful to decision makers?

1 reference

https://pubmed.ncbi.nlm.nih.gov/19089488

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19089488

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pattern of infliximab utilization in rheumatoid arthritis patients at an academic medical center

1 reference

https://pubmed.ncbi.nlm.nih.gov/19089488

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Outcomes after switching from one anti–tumor necrosis factor α agent to a second anti–tumor necrosis factor α agent in patients with rheumatoid arthritis: Results from a large UK national cohort study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19089488

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19089488

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition

1 reference

https://pubmed.ncbi.nlm.nih.gov/19089488

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The initial validation of a Markov model for the economic evaluation of (new) treatments for rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19089488

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The economic burden associated with osteoarthritis, rheumatoid arthritis, and hypertension: a comparative study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19089488

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapeutic strategies for rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19089488

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19089488

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biological agents for rheumatoid arthritis: targeting both physical function and structural damage

1 reference

https://pubmed.ncbi.nlm.nih.gov/19089488

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10067-008-1060-4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19089488%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19089488%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q83001629&oldid=1832375326"